Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

AKRO
Akero Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open
May 15, 2025 12:36:36 PM EDT
39.99USD+5.570%(+2.11)708,260
39.92Bid   45.00Ask   5.08Spread
Pre-market
May 14, 2025 9:08:30 AM EDT
39.00USD+2.957%(+1.12)0
After-hours
May 14, 2025 4:34:30 PM EDT
38.80USD+2.564%(+0.97)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 4, 2022
04:05PM EST  Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. E.T.   GlobeNewswire Inc
Nov 26, 2021
05:29PM EST  Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday December 2 at 3:30 p.m. E.T.   GlobeNewswire Inc
Nov 15, 2021
11:09AM EST  Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $29   Benzinga
10:51AM EST  HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Lowers Price Target to $62   Benzinga
Nov 12, 2021
08:23AM EST  Akero Highlights Presentation Of New Analysis Of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence Of Histological Improvement In EFX-treated NASH Patients After 16 Weeks Of Treatment   Benzinga
08:01AM EST  Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks   GlobeNewswire Inc
07:20AM EST  Akero Therapeutics Q3 EPS $(0.70) Down From $(0.63) YoY   Benzinga
07:00AM EST  Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported third quarter financial results for the period ending September 30, 2021.   GlobeNewswire Inc
Oct 20, 2021
08:16AM EDT  The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review   Benzinga
Oct 19, 2021
04:15PM EDT  Akero Therapeutics Reports Received FDA Fast Track Designation For Efruxifermin For Treatment Of NASH   Benzinga
04:15PM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH).   GlobeNewswire Inc
06:51AM EDT  Morgan Stanley Downgrades Akero Therapeutics to Equal-Weight, Announces $27 Price Target   Benzinga
Oct 5, 2021
08:16AM EDT  Akero Therapeutics To Present At H.C. Wainwright 5th Annual NASH Investor Conference Oct. 12   Benzinga
08:00AM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that Tim Rolph, Akeros Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 12:00 p.m. (ET).   GlobeNewswire Inc
Sep 10, 2021
07:36PM EDT  B of A Securities Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $40   Benzinga
Sep 9, 2021
09:13AM EDT  Akero Therapeutics Sponsored Study Titled 'A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)' Posted To ClinicalTrials.Gov; Study Is Recruiting   Benzinga
Sep 7, 2021
08:00AM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET).   GlobeNewswire Inc
Aug 16, 2021
06:40AM EDT  HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Lowers Price Target to $64   Benzinga
Aug 13, 2021
08:13AM EDT  Akero Therapeutics Q2 Loss Per Share $0.83 Vs Loss $0.57 Last Year   RTTNews
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
07:06AM EDT  Akero Therapeutics Q2 EPS $(0.83) Down From $(0.57) YoY   Benzinga
07:00AM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending June 30, 2021.   GlobeNewswire Inc
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
08:00AM EDT  Fate Therapeutics Appoints Yuan Xu to its Board of Directors   GlobeNewswire Inc
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
08:11AM EDT  Akero Therapeutics Appoints Judy Chou To Its Board   RTTNews
08:00AM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment ofJudy Chou, Ph.D., to its board of directors as an independent director.   GlobeNewswire Inc
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
01:24PM EDT  Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment   Benzinga
11:10AM EDT  Akero Therapeutics Highlights Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment   Benzinga
Jun 25, 2021
11:32AM EDT  Akero Therapeutics Presents at the American Diabetes Association's 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-   Benzinga
11:30AM EDT  Akero Therapeutics Presents at the American Diabetes   GlobeNewswire Inc
Jun 21, 2021
11:33AM EDT  Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients   Benzinga
08:00AM EDT  Akero Therapeutics Presents Analyses at the 2021 International   GlobeNewswire Inc
Jun 1, 2021
08:10AM EDT  Akero Therapeutics To Present Efruxifermin Results Showing Histologic Improvement In EFX-Treated F4 Cirrhotic Patients As Late-Breaker Oral Presentation At The 2021 International Liver Congress   Benzinga
08:00AM EDT  Akero Therapeutics to Present Efruxifermin (EFX) Results Showing   GlobeNewswire Inc
May 28, 2021
04:05PM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. (ET).   GlobeNewswire Inc
May 26, 2021
07:10AM EDT  ARKO Corp. Announces Extended Wholesale Agreement With Core-Mark   Benzinga
May 18, 2021
06:11AM EDT  Akero Therapeutics Files for Potential Mixed Shelf Offering; Size Not Disclosed   Benzinga
May 13, 2021
07:10AM EDT  Akero Therapeutics Q1 EPS $(0.43) Down From $(0.42) YoY   Benzinga
07:00AM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported first quarter financial results for the period endingMarch 31, 2021.   GlobeNewswire Inc
Apr 26, 2021
08:00AM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment ofYuan Xu, Ph.D., to its board of directors as an independent director.   GlobeNewswire Inc
Mar 23, 2021
08:12AM EDT  Akero Therapeutics Reports First Patient Randomized For Dosing In Phase 2b Study Of Efruxifermin In F2/F3 NASH Patients   Benzinga
08:00AM EDT  Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the first patient has been randomized for dosing in its Phase 2b clinical study of Efruxifermin (EFX) in the treatment of patients with F2/F3 NASH (the HARMONY study).   GlobeNewswire Inc
07:48AM EDT  Morgan Stanley Maintains Overweight on Akero Therapeutics, Lowers Price Target to $63   Benzinga
07:04AM EDT  HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $68   Benzinga
Mar 22, 2021
04:03PM EDT  Akero Therapeutics Reports Histological Improvements In Cirrhotic NASH Patients: '33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH'   Benzinga
04:01PM EDT  -- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH --   GlobeNewswire Inc
06:31AM EDT  Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients   Benzinga
06:30AM EDT  Akero Therapeutics to Announce New Data from an Evaluation of   GlobeNewswire Inc
Mar 18, 2021
08:52AM EDT  Canaccord Genuity Maintains Buy on Akero Therapeutics, Lowers Price Target to $46   Benzinga
Mar 17, 2021
07:08AM EDT  Chardan Capital Maintains Buy on Akero Therapeutics, Raises Price Target to $81   Benzinga
06:52AM EDT  HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Lowers Price Target to $61   Benzinga
Mar 16, 2021
08:07AM EDT  Akero Therapeutics Q4 EPS $(0.86) Down From $(0.55) YoY   Benzinga
08:00AM EDT  Akero Therapeutics,Inc.(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported fourth quarter and full year financial results for the period endingDecember 31, 2020.   GlobeNewswire Inc
Feb 26, 2021
10:40AM EST  Guggenheim Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $54   Benzinga
Feb 23, 2021
04:06PM EST  Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in   PR Newswire
Jan 4, 2021
04:05PM EST  Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference   Business Wire
Nov 24, 2020
04:09PM EST  Akero Therapeutics To Present At Evercore ISI 3rd Annual HealthCONx Virtual Conference Dec. 3   Benzinga
04:05PM EST  Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference   Business Wire
Nov 13, 2020
08:08AM EST  Akero : Phase 2a BALANCED Study Shows Potential Of Efruxifermin As Foundational NASH Monotherapy   RTTNews
08:06AM EST  10 Biggest Price Target Changes For Friday   Benzinga
08:02AM EST  Akero Presents Additional Positive Data From Phase 2a BALANCED Study Demonstrating Potential Of Efruxifermin As Foundational NASH Monotherapy   Benzinga
06:21AM EST  HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $64   Benzinga
Nov 12, 2020
04:13PM EST  Akero Therapeutics Q3 EPS $(0.63) Down From $(0.56) YoY   Benzinga
04:06PM EST  Akero Therapeutics Reports Third Quarter 2020 Financial Results   PR Newswire
Oct 21, 2020
04:06PM EDT  Akero Therapeutics TO Present At Credit Suisse Healthcare Conference On Nov. 9, Jeffries Global Healthcare Conference On Nov. 17   Benzinga
04:05PM EDT  Akero Therapeutics To Present At Upcoming Conferences In November   PR Newswire
Oct 19, 2020
10:14AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Oct 16, 2020
07:36AM EDT  Akero Therapeutics Gets European Medicines Agency Priority Medicines Designation For Efruxifermin In NASH   RTTNews
07:32AM EDT  Akero Therapeutics Reports EMA Priority Medicines Designation For Efruxifermin In Carbio-Metabolic Non-Alcoholic Steatohepatitis   Benzinga
07:30AM EDT  Akero Therapeutics Receives European Medicines Agency Priority Medicines   PR Newswire
Oct 2, 2020
07:31AM EDT  Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting 2020 Nov. 13-16   Benzinga
07:30AM EDT  Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin   PR Newswire
Sep 30, 2020
08:07AM EDT  Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study   Benzinga
08:03AM EDT  Akero Therapeutics Completes Enrollment Of Cohort Of Cirrhotic (F4) Patients In Balanced Study   RTTNews
08:01AM EDT  Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In   PR Newswire
Sep 28, 2020
04:05PM EDT  Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual   PR Newswire
Sep 24, 2020
07:35AM EDT  Akero Plans To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design   RTTNews
07:33AM EDT  Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance   Benzinga
07:30AM EDT  Akero Therapeutics To Continue Efruxifermin Development With Innovative   PR Newswire
Sep 10, 2020
06:56AM EDT  Morgan Stanley Initiates Coverage On Akero Therapeutics with Overweight Rating, Announces Price Target of $70   Benzinga
Sep 9, 2020
04:05PM EDT  Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare   PR Newswire
Aug 12, 2020
04:17PM EDT  Akero Therapeutics Q2 EPS $(0.57) Up From $(2.21) YoY   Benzinga
04:06PM EDT  Akero Therapeutics Reports Second Quarter 2020 Financial Results   PR Newswire
Jul 21, 2020
11:01AM EDT  Research Published in Cell Reports Medicine Highlights Potential of Akero   PR Newswire
Jul 20, 2020
08:43AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:35AM EDT  HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $62   Benzinga
Jul 18, 2020
04:22PM EDT  Notable Insider Buys: Bed Bath & Beyond, Poseida Therapeutics And More   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC